This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DaVita Stock Down Post Q3 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.
DaVita HealthCare (DVA) Q3 Earnings Lag Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -23.71% and +0.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Technology and Cost Discipline Lift DaVita's Q3 Earnings?
by Zacks Equity Research
DVA's third-quarter 2025 performance is likely to benefit from technology upgrades and cost control while battling high missed treatments and low volume growth.
DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
DaVita HealthCare (DVA) concluded the recent trading session at $128.05, signifying a +1.72% move from its prior day's close.
DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $126.62 in the latest trading session, marking a +2.19% move from the prior day.
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $127.89, denoting a -2.4% move from the preceding trading day.
DaVita HealthCare (DVA) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $128.14, denoting a -2.3% move from the preceding trading day.
DaVita HealthCare (DVA) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the latest trading session, DaVita HealthCare (DVA) closed at $132.87, marking a +1.75% move from the previous day.
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Addus HomeCare and The Pennant
by Zacks Equity Research
Quest Diagnostics, DaVita, Addus HomeCare, and The Pennant Group are positioned to benefit from telehealth, AI adoption, and rising demand in the $747B home healthcare market.
4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends
by Debanjana Dey
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.
DaVita HealthCare (DVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw DaVita HealthCare (DVA) settling at $132.83, representing a +1.28% change from its previous close.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita HealthCare (DVA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the latest trading session, DaVita HealthCare (DVA) closed at $128, marking a -1.62% move from the previous day.
Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DaVita HealthCare (DVA) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $132.26 in the latest trading session, marking a -3.26% move from the prior day.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cardinal Health to Acquire Solaris Health for Urology Expansion
by Zacks Equity Research
CAH is set to buy Solaris Health for $2.4B, boosting urology presence with 750+ providers and expanding Specialty Alliance reach.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are Investors Undervaluing DaVita (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.